Statistics from Altmetric.com
Q Does augmentation with antipsychotics improve outcome for people with refractory obsessive-compulsive disorder who are not responding to serotonin reuptake inhibitor monotherapy?
Systematic review with meta-analysis.
PubMed and PsychINFO (1967–2005), EMBASE (1974–2000) and the Cochrane Central Register of Controlled Trials (Issue 3, 2005). Reference lists were hand searched.
Study selection and analysis:
Eligible studies were double blinded, randomised controlled trials (RCTs) that compared augmentation with antipsychotic versus placebo in adults with obsessive-compulsive disorder that had not responded to ⩾2 months serotonin reuptake inhibitor (SRI) monotherapy, and that used the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) as an outcome measure. Pooled absolute risk difference (RD) was used to analyse proportion of treatment responders and number needed to treat (NNT) was reported.
Response (defined as ⩾35% reduction in Y-BOCS score).
Nine RCTs met inclusion criteria (278 people). Antipsychotics tested …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.